title: Treatment with benznidazole and its immunomodulating effects on Trypanosoma cruzi-infected rats.
abstract: Because benznidazole (BZL) was found to downregulate nitric oxide (NO) and cytokine synthesis by murine macrophages, we analyzed the potential immunological repercussions of BZL treatment in Trypanosoma cruzi-infected rats. To evaluate whether the effects of BZL were also observed in the presence of an immunostimulating cytokine, four groups of acutely infected rats were subjected to one of the following 20-day therapeutic schedules: (1) a curative BZL oral regimen, (2) recombinant interferon (IFN-gamma) injections, (3) a suboptimal BZL regimen (25% of curative dose), (4) the latter plus IFN-gamma. All BZL doses markedly reduced NO-derived metabolites either in the circulation or in cultured macrophage supernatants. This was observed in rats simultaneously treated with IFN-gamma, which contrasted with the augmented NO production seen in animals given this cytokine alone. The untreated rats, and groups receiving monotherapy with IFN-gamma or 25% BZL, had increased circulating interleukin (IL)-1beta and IL-2 levels, which were reduced in those given BZL plus IFN-gamma. Although combined treatment failed to cause the virtually undetectable blood parasite levels induced by optimal BZL doses, chronic myocardial lesions were reduced to the same extent as in those receiving the curative schedule. The beneficial effects of BZL in this trypanosomiasis may also depend on some immunomodulating influences.
authors.affiliation: Instituto de Inmunología, Facultad de Ciencias Médicas de Rosario, Argentina.
authors.forename: E
authors.initials: E
authors.lastname: Piaggio
authors.forename: E
authors.initials: E
authors.lastname: Roggero
authors.forename: M
authors.initials: M
authors.lastname: Pitashny
authors.forename: J
authors.initials: J
authors.lastname: Wietzerbin
authors.forename: O A
authors.initials: OA
authors.lastname: Bottasso
authors.forename: S S
authors.initials: SS
authors.lastname: Revelli
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000284:Administration, Oral; D000818:Animals; D002478:Cells, Cultured; D014355:Chagas Disease / Q000097:blood / Q000188:drug therapy*; D016207:Cytokines / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D004359:Drug Therapy, Combination; D006321:Heart / Q000469:parasitology; D007371:Interferon-gamma / Q000627:therapeutic use*; D017737:Macrophages, Peritoneal / Q000469:parasitology / Q000473:pathology; D008297:Male; D009205:Myocarditis / Q000469:parasitology / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D009569:Nitric Oxide / Q000378:metabolism; D009593:Nitroimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D018512:Parasitemia / Q000188:drug therapy; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins; D014344:Trypanocidal Agents / Q000627:therapeutic use*; D014349:Trypanosoma cruzi / Q000502:physiology
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D009593:Nitroimidazoles; D011994:Recombinant Proteins; D014344:Trypanocidal Agents; D009569:Nitric Oxide; D007371:Interferon-gamma; C009999:benzonidazole